Last reviewed · How we verify
PF-07062119 (pf-07062119)
PF-07062119 (generic name: pf-07062119) is a Selective pathway inhibitor drug developed by Pfizer Inc.. It is currently in discontinued development.
PF-07062119 is a selective inhibitor targeting a key molecular pathway in gastrointestinal cancer cell proliferation.
PF-07062119 is a selective small-molecule inhibitor developed by Pfizer for oncology indications, specifically targeting advanced gastrointestinal and colorectal tumors. The compound was designed to block a key molecular pathway involved in cancer cell proliferation and survival, though the precise target and mechanism remain proprietary. The program entered Phase 1 clinical testing with 79 patients but was terminated, indicating the compound did not advance to later-stage development. No FDA approval was achieved, and the drug remains in discontinued status with no commercial availability. The termination suggests either safety concerns, lack of efficacy, or strategic portfolio decisions by Pfizer. This profile represents a failed oncology asset with limited public clinical data.
At a glance
| Generic name | pf-07062119 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Selective pathway inhibitor |
| Target | Undisclosed molecular target (pathway inhibitor in gastrointestinal cancer) |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
PF-07062119 was developed as a targeted therapeutic agent designed to interfere with a specific molecular pathway implicated in the progression of gastrointestinal malignancies, including colorectal and gastric cancers. The compound functions as a selective inhibitor, meaning it preferentially blocks its intended target while minimizing off-target effects. By disrupting this pathway, the drug aims to slow or halt cancer cell growth and survival. However, detailed mechanistic information—including the specific molecular target, binding kinetics, and cellular effects—has not been disclosed in public literature, limiting independent assessment of its pharmacological rationale.
Approved indications
Pipeline indications
- Advanced or metastatic gastrointestinal tumors — Phase 1
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07062119 CI brief — competitive landscape report
- PF-07062119 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-07062119
What is PF-07062119?
How does PF-07062119 work?
Who makes PF-07062119?
What is the generic name of PF-07062119?
What drug class is PF-07062119 in?
What development phase is PF-07062119 in?
What does PF-07062119 target?
Related
- Drug class: All Selective pathway inhibitor drugs
- Target: All drugs targeting Undisclosed molecular target (pathway inhibitor in gastrointestinal cancer)
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing